ArticleFrontiers in oncology2024

Remarkable response to third-generation EGFR-TKI plus crizotinib in a patient with pulmonary adenocarcinoma harboring EGFR and ROS1 co-mutation: a case report.

Zhiming Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.